Intra-Cellular Therapies v. Hetero: ANDA Patent Litigation Consolidated in NJ

Case Overview

Introduction: A Pharmaceutical Patent Battle Over a Leading Antipsychotic

When Intra-Cellular Therapies, Inc. (ITCI) filed suit against Hetero USA, Inc., Hetero Labs Ltd., and Hetero Labs Limited in the District of New Jersey on November 1, 2024, it was the latest chapter in one of the most strategically significant pharmaceutical patent infringement campaigns of 2024. At the center of the dispute: CAPLYTA® (lumateperone) capsules — a branded atypical antipsychotic approved for major depressive episodes and schizophrenia — and three recently issued U.S. patents protecting its formulation and composition.

Within 70 days, the case closed — not through trial or settlement, but through consolidation with a broader coordinated ANDA litigation involving at least seven generic manufacturers simultaneously challenging ITCI’s lumateperone patent portfolio.

For patent litigators, IP professionals, and pharmaceutical R&D teams, this case offers a revealing window into ITCI’s multi-front enforcement strategy, the procedural mechanics of consolidated Hatch-Waxman litigation, and the competitive stakes surrounding a high-value CNS drug franchise.

The Parties

The Patents at Issue

This litigation involved three U.S. patents covering lumateperone formulations and compositions:

• • U.S. Patent No. 12,128,043 B2 (Application No. 18/602,981)
• • U.S. Patent No. 12,122,792 B2 (Application No. 18/240,951)
• • U.S. Patent No. 12,090,155 B2 (Application No. 18/494,754)

These recently issued patents reflect ITCI’s active lifecycle management strategy to extend protection for CAPLYTA®.

Litigation Timeline & Procedural History

Case No. 3:24-cv-10237 was filed on November 1, 2024, and formally closed on January 10, 2025 — a remarkably brief 70-day lifespan that reflects not a substantive resolution, but a procedural consolidation.

The broader litigation context is essential to understanding the timeline. ITCI had already initiated related ANDA actions beginning March 27–28, 2024, targeting Aurobindo, Alkem, Dr. Reddy’s Laboratories, MSN Laboratories, Sandoz, and Zydus — in addition to Hetero — across Civil Action Nos. 3:24-cv-04264, 3:24-cv-04312, 3:24-cv-04314, 3:24-cv-04317, 3:24-cv-04325, 3:24-cv-04327, and 3:24-cv-04330.

A second wave of related actions was filed on August 29, 2024, across Civil Action Nos. 3:24-cv-08845 through 3:24-cv-08856, again targeting the same group of seven generic defendants including Hetero.

The November 2024 case — 3:24-cv-10237 — was subsequently consolidated into the lead action, 3:24-cv-04264, alongside all related civil actions. The basis of termination was case consolidation, which is standard procedure in multi-defendant Hatch-Waxman litigation to promote judicial efficiency and consistent claim construction.

The venue selection — the District of New Jersey — is deliberate and significant, as it is among the most active and experienced jurisdictions for pharmaceutical patent litigation in the United States.

The Verdict & Legal Analysis

Outcome

Case No. 3:24-cv-10237 was closed via consolidation into the lead ANDA litigation docket (3:24-cv-04264). No damages were awarded, no injunction was separately issued, and no trial occurred at this stage. The substantive infringement claims against Hetero are being adjudicated within the consolidated proceeding.

Verdict Cause Analysis

The underlying cause of action is patent infringement, specifically arising from Hetero’s ANDA filing for generic lumateperone capsules. Under the Hatch-Waxman framework, an ANDA filer’s Paragraph IV certification — asserting that a brand’s listed patents are invalid or will not be infringed — constitutes a technical act of infringement triggering the brand’s right to sue and obtain a 30-month stay of FDA approval.

The three asserted patents (US12128043B2, US12122792B2, US12090155B2) appear to be recently issued continuation patents. This reflects ITCI’s strategy of maintaining a layered patent estate around CAPLYTA® — a practice sometimes called “evergreening” by critics, but which represents legitimate patent prosecution strategy when new claims are supported by the original disclosure. For litigators, the recency of these patents means the prosecution history will be closely scrutinized during claim construction, with potential prosecution history estoppel arguments available to generic defendants.

Legal Significance

The consolidation of seven separate generic manufacturer actions into a single lead proceeding has significant implications for claim construction uniformity. A single Markman hearing in the lead case will bind all defendants, meaning the outcome of claim construction will simultaneously affect ITCI’s infringement case against Alkem, Aurobindo, DRL, MSN, Sandoz, Zydus, and Hetero. For patent litigators, this underscores the outsized strategic importance of Markman proceedings in consolidated Hatch-Waxman cases.

Additionally, the fact that ITCI asserted three distinct patents across multiple filing waves suggests a deliberate effort to ensure that even if earlier-filed patents face successful invalidity challenges, later-issued continuation patents may provide independent infringement hooks.